{
    "nct_id": "NCT06227377",
    "official_title": "A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients With Solid Tumors With KRASG12D Mutation",
    "inclusion_criteria": "* Pathologically documented, locally advanced or metastatic malignancy with KRAS G12D mutation identified through molecular testing (NGS- or PCR-based) with a Clinical Laboratory Improvement Amendments-certified (or equivalent) diagnostic\n* Part 1: - Advanced solid tumors with at least 1 prior systemic therapy\n* Evaluable or Measurable disease per RECIST 1.1.\n* Parts 2 and 3: Measurable disease per RECIST 1.1.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n* Adequate organ function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with a KRAS inhibitor\n* Active brain metastases or carcinomatous meningitis\n* History of other malignancy within 2 years\n* Significant cardiovascular disease\n* Disease or disorder that may pose a risk to patient's safety\n\nOther protocol-defined Inclusion/Exclusion Criteria may apply",
    "miscellaneous_criteria": ""
}